Shataverins

Other Names

AheruballiAshadi beruAsparagus fernAsparagus racemosus steroidal saponinsAtmooliBahusutaBhiruButtermilk rootChatavaliClimbing asparagusDongriIndeevariInli-chediInlichediKairuwaKuriloMadabhanjaniMajjigegaddeNarayaniNarbodhNepal KuriloNorkantoNunggareiPilli-gaddaluSadavareSahastramuliSasar muliSatamuliSatavarSatavariSatawarSatawar (Urdu)SatawariSathavariSatmuliSatomulSej-panShakakulShaqaqulShatamuliShatavariShatavarinShatavarin IShatavarin IIShatavarin IIIShatavarin IVShatavarin IXShatavarin VShatavarin VIShatavarin VIIShatavarin VIIIShatavarin XShatavarinsShatawarShatawariShatmoolShatmooliShatmuliShatpadiShatuliShatviryaShimaishadavariSukshamapatraTian Men DongToala-gaddaluVrishyaWater rootWild asparagusWild carrotYerrwuwu

Synopsis

Shatavarins: A Comprehensive Reference

1. Identity, Botanical Source, and Nomenclature

Shatavarins (also spelled shataverins, shatavaríns, or shatavarins) are a chemically defined family of steroidal saponins that constitute the principal bioactive fraction of the medicinal plant Asparagus racemosus Willd. Asparagus racemosus, commonly known as Shatavari, is an established Ayurvedic plant whose bioactivity is credited to its steroidal saponins, generally referred to as shatavarins, exerting adaptogenic and estrogenic effects. Medicinal properties of Asparagus racemosus (vernacular name: Shatavari) are attributed to its steroidal saponins called shatavarins.

The Ayurvedic Pharmacopoeia of India identifies the botanical origin of Shatavari as the tuberous root of Asparagus racemosus. Asparagus racemosus belongs to the Asparagaceae family and is abundant in Nepal, India, and Sri Lanka, where it is an important medicinal herb of Indian Ayurveda. The climbing A. racemosus plant grows wild, reaching 2 m in height, and is cultivated in India and other tropical and subtropical Asian and African countries; it has also been found in the Himalayan Mountains. It is extensively branched with needle-like leaves, and bears fragrant small white flowers and berries.

The plant is known under numerous vernacular names across the subcontinent. Common names include Shatavari, Satawar, Satamuli (Sanskrit, Bengali, and Gujarati), Shatamuli (Hindi), as well as buttermilk root, climbing asparagus, water root, wild asparagus, and Indian asparagus root. It is also commonly known as Satawar, Satamuli, and Satavari, and is found at low altitudes throughout India.

1.1 The Shatavarin Series: Individual Compounds

Steroidal saponins (shatavarinI–X) are the main active components of Shatavari root extract with pharmacological activity. Structurally, all shatavarins share a core steroidal aglycone (sapogenin) unit to which varying sugar chains are attached. The aglycone unit is sarsasapogenin.

Five steroidal saponins, shatavarins VI–X, together with five known saponins — shatavarin I (or asparoside B), shatavarin IV (or asparinin B), shatavarin V, immunoside, and schidigera saponin D5 (or asparanin A) — have been isolated from the roots of Asparagus racemosus by RP-HPLC and characterized by spectroscopic (1D and 2D NMR experiments) and spectrometric (LCMS) methods.

Shatavarin I: The primary glycoside linked to sarsasapogenin is shatavarin I, which contains 3-glucose and rhamnose moieties. An earlier description noted that in shatavarin I, three glucose and one rhamnose molecules are attached, whereas shatavarin IV possesses two glucose and one rhamnose molecules.
Shatavarin IV: Shatavarin IV is a glycoside derivative of sarsasapogenin that contains more than 15% saponins. Shatavarin IV saponin has three unbranched sugars — two glucose and one rhamnose — moiety attached with the C-3 portion of the aglycone (sarsasapogenin) and lacks an acyl domain in its molecule. Among its steroidal saponins, shatavarin IV is regarded as a key active molecule and has shown activity against specific biological targets, such as Core 2 GlcNAc transferase inhibition.
Shatavarins V–X: Shatavarin V, asparins, asparosides, curillins, curillosides, and oligospirostanoside (Immunoside) have all recently been discovered. In addition, five novel steroidal saponins, shatavarins VI to X, were identified from the roots of Shatavari, along with five known saponins.

Based upon the aglycone portion, the phytosteroidal saponins found in Asparagus belong to the class of spirostanol or furostanol, both being glycosidic. Protodioscin is a principal steroidal furostanol saponin constituent of Asparagus.

1.2 Other Co-occurring Bioactive Constituents

Shatavarins do not act in isolation. The complete phytochemical profile of Asparagus racemosus root includes a wide array of secondary metabolites. The plant constitutes steroidal saponins, steroids, alkaloids, flavonoids, cyclic hydrocarbons, tannins, anthraquinones, polysaccharides, oligospirostanoside, trace minerals, and essential oils. The bioactive constituents comprise steroidal saponins (shatavarins I–IV), known antioxidants such as racemosides, racemosol, racemofuran, and asparagamine A, and phytoestrogens including rutin, kaempferol, genistein, daidzein, and quercetin. Compounds with medicinal values isolated from Asparagus also include racemofuran, asparagamine, and racemosol. The plant contains bioactive metabolites such as fructo-oligosaccharides, polysaccharides, asparosides, shatavarins, sapogenins, racemosols, isoflavones, glycosides, mucilage, and fatty acids, with saponin being one of the main active constituents.

1.3 Common Forms and Preparations

Beyond its traditional uses, Asparagus racemosus has become a commercially important plant due to its wide therapeutic spectrum and increasing market value; Shatavari-based formulations are commonly used for reproductive health, hormonal balance, lactation support, gastrointestinal protection, and stress management. Marketed preparations include standardized root extracts in capsule form, typically standardized to a defined total shatavarin content. A key approach in modern clinical trials is the use of a standardized Shatavari root extract containing >10% shatavarins; standardization at this level provides greater consistency in dosing and enhances the reliability of observed effects. A novel Asparagus root formulation, Shevari4T®, has been developed with Shatavarin IV content exceeding 7.4%, which promises to deliver the goodness of Shatavari especially for women. Raw root powder, coarse-ground root (churna), and aqueous decoctions are the classical preparations used in traditional settings.

2. Traditional and Historical Use

Shatavari has recorded use dating back to the Rig Veda — one of the oldest extant texts in any Indo-European language (c. 1500–1200 BCE) — and its use in Ayurveda is outlined in the great texts of the Brihat Trayi: the Charaka Samhita (600 BCE), Sushruta Samhita (500 BCE), and Ashtanga Sangraha (400–500 AD), as well as texts of the Laghu Trayi: the Sharngadhara Samhita (14th century AD).

The name Shatavari is often translated as "she who possesses a hundred husbands," an expression reflecting its long-standing association with female strength and resilience in classical texts. According to Ayurveda, Shatavari is described as a rasayana — a category of herbs associated with nourishment and rejuvenation.

A study of ancient classical Ayurvedic literature claimed several therapeutic attributes for the root of A. racemosus and has been specially recommended in cases of threatened abortion and as a galactogogue. The root has been referred to as bitter-sweet, emollient, cooling, nervine tonic, constipating, galactogogue, aphrodisiac, diuretic, rejuvenating, carminative, stomachic, antiseptic, and as a general tonic.

Beneficial effects of the root are suggested in nervous disorders, dyspepsia, diarrhoea, dysentery, tumors, inflammations, hyperdipsia, neuropathy, hepatopathy, cough, bronchitis, hyperacidity, and certain infectious diseases.

Asparagus racemosus has been extensively utilized in traditional medicine systems including Ayurveda, Unani, and Siddha. Historical references in the Tamil Siddha compilations echo similar uses: as a galactagogue to support lactation, and as a gentle nervine tonic during menopause.

Ancient texts like the Charaka Samhita and Ashtanga Hridayam endorse its use for women's health disorders. Beyond reproductive health, Shatavari is esteemed as an Ayurvedic rasayana, offering anti-aging, immune-boosting, and rejuvenating benefits. Asparagus racemosus is recommended in Ayurvedic texts for prevention and treatment of gastric ulcers, dyspepsia, and as a galactogogue; it has also been used by some Ayurvedic practitioners for nervous disorders, inflammation, liver diseases, and certain infectious diseases.

3. Key Constituents and Mechanisms of Action

3.1 Phytoestrogenic / Hormonal Mechanisms

Shatavarins are steroidal saponins in structure that have affinity towards estrogen receptors and exhibit estrogen-like activity, which helps in regulating overall hormonal function. Phytoestrogens in Shatavari are believed to modulate estrogenic activity by binding to estrogen receptors. Shatavarins I–V, the steroidal saponins, may be responsible for the hormonal-like effect of Shatavari and explain its traditional use as a reproductive tonic.

In the lactation context, a key regulator of prolactin production is estrogens, which enhance the growth of prolactin-producing cells and stimulate prolactin production directly as well as by suppressing dopamine; Shatavari also contains tryptophan, an essential amino acid that may stimulate prolactin production, leading to increased milk production.

3.2 Immunomodulatory Mechanisms

In vitro produced shatavarin stimulated immune cell proliferation and IgG secretion in a dose-dependent manner. It stimulated interleukin (IL)-12 production and inhibited production of IL-6; it also had strong modulatory effects on Th1/Th2 cytokine profile, indicating its potential application for immunotherapies where Th1/Th2 balance is envisaged. Polysaccharide fractions from its roots stimulate macrophage phagocytic activity and increase immunoglobulin production, while simultaneously regulating T-helper and T-regulatory cell activity.

3.3 Anti-inflammatory and Antioxidant Mechanisms

Shatavari demonstrates significant antioxidant potential, providing protection against oxidative damage, particularly in lipid peroxidation and protein oxidation. Shatavari extracts exhibit antioxidant activity against free radical-induced damage during gamma radiation in rat liver mitochondria; the P3 fraction shows distinct activity against lipid peroxidation, while the crude extract is more effective in inhibiting protein oxidation.

Shatavarin IV has been investigated for direct anti-inflammatory activity in cell models. In LPS-induced cells treated with shatavarin IV, IL-6 and TNFα levels were reduced by 46% and 50%, respectively, and those of IL-10 and TGF-β were upregulated by 2.74 and 4.4 times, with significant reductions in ROS and NO levels.

3.4 Gastroprotective Mechanisms

Traditionally described as a pittashamaka (pitta-dosha pacifying) herb, Shatavari demonstrates gastroprotective and anti-ulcer activity; it reduces gastric acid secretion, enhances mucus secretion, and inhibits gastric wall cell damage through flavonoid-mediated antioxidant action. In Ayurveda, Shatavari is used for dyspepsia and stimulating gastric emptying, similar to the synthetic dopamine antagonist metoclopramide. Various extracts from the root of A. racemosus have been shown to cause contraction of smooth muscles of rabbit duodenum, guinea pig ileum, and rat fundal strip without affecting peristaltic movement; these actions were found to be similar to that of acetylcholine and were blocked by atropine, suggesting a cholinergic mechanism of action.

3.5 Neuroprotective Mechanisms (Preclinical)

Administration of K-252a (a TrkB inhibitor) dampened the neuroprotective effect of shatavarin IV, indicating that shatavarin IV exerts its effect via the TrkB-BDNF axis; the results suggested that shatavarin IV probably exerted its effect by salvaging endogenous BDNF with subsequent docking to TrkB as a BDNF–shatavarin IV complex. In silico docking of the shatavarin IV–BDNF complex with TrkB resulted in a considerably strong binding energy of −10.3 kcal/mole, whereas that of shatavarin IV alone was comparatively weaker at −6.9 kcal/mole. These findings are from cell culture and computational studies and have not been confirmed in humans.

3.6 Adjuvant Activity

In a murine model, Quil-A (10 μg) and Shatavarin IV (40 μg) saponin produced a better humoral immune response. This indicated the balanced nature of the Shatavarin IV saponin steroidal nucleus and sugar chains in its chemical structure. Shatavarin IV exhibited more hemolytic activity at a very lower concentration due to its core steroidal nucleus; this promotes the binding of saponin with the phospholipid membrane of red blood cells and initiates hemolysis by a membrane perturbation mechanism.

4. Scientific Evidence by Health Area

4.1 Lactation (Galactogogue Effect)

This represents one of the most clinically investigated uses of Shatavari and the shatavarins. The extract of Shatavari has been shown to increase both the weight of mammary lobulo-alveolar tissue and milk yield in animal experiments. The presence of steroidal saponins and sapogenins constituents has been shown to directly contribute to the lactogenic effect of Asparagus racemosus.

In humans, a landmark early study employed a randomized controlled design. A multicentric, randomized, double-blind, placebo-controlled parallel study was designed by Sharma et al. (1996) to observe a rise in serum prolactin (PRL) levels as the primary outcome variable. The results of this clinical study showed that oral administration of the research drug had a definite positive impact on the primary parameter — the prolactin hormone level in lactating mothers — with the increase in mean prolactin hormone level in the research group being three times more than that of the control group.

A more recent randomized, double-blind, placebo-controlled trial enrolled postpartum women to further examine these effects. This prospective, randomized, double-blind, placebo-controlled study enrolled 120 (intent-to-treat) postpartum women (≥37 weeks' gestation, aged 20–40 years) with uncomplicated vaginal or cesarean deliveries who intended to breastfeed; participants received either Shatavari root extract (SHT; 300 mg) or placebo capsules twice daily for 72 hours postpartum. Shatavari root extract significantly enhanced lactation outcomes in postpartum women by increasing milk volume and maternal satisfaction, indicating its potential as a safe, effective galactagogue.

A separate double-blind, placebo-controlled trial evaluated a Shatavari-and-oats formulation (Shavari Bar®). A prospective, randomized, parallel-group, double-blind, placebo-controlled study was conducted at two centers in women with gestational age 37 weeks or more who intended to breastfeed; 104 women were screened, of which 78 were randomized to receive either a bar containing Shatavari and oats (n=39, study) or an identical placebo bar (n=39, control). Findings indicated that the Shavari Bar increases breast milk production in nursing mothers more effectively than a placebo, with a statistically significant increase in breast milk volume observed in the study arm. Importantly, no maternal or neonatal adverse events were observed in the study.

Evidence assessment: Multiple small-to-moderate randomized controlled trials support a positive lactogenic effect, including increases in serum prolactin and measurable breast milk volume. The body of evidence is encouraging but limited by small sample sizes and short treatment durations. A review of the evidence for the efficacy of popular pharmaceutical and herbal galactagogues revealed a dearth of high-quality clinical trials and mixed results, and controlled trials and analyses investigating these medicines are urgently warranted.

4.2 Perimenopausal and Menopausal Symptoms

Evidence from the Women's Health Initiative (WHI) and subsequent studies has linked prolonged HRT use to increased risks of breast cancer, thromboembolism, and cardiovascular events, which has intensified the demand for safer alternatives. In this context, clinical investigation of Shatavari root extract (standardized to shatavarins) for menopausal symptoms has grown substantially.

A prospective, randomized, double-blind, placebo-controlled trial assessed an 8-week intervention. The study aimed to assess the efficacy and safety of 8-week oral administration of Shatavari root extract 300 mg once daily in women with perimenopausal symptoms; 120 women were screened, 80 were eligible participants and randomly assigned to receive either Shatavari root extract (SHT; n=40) or placebo (PL; n=40), and 73 participants completed the study per protocol. Hot flash frequency, one of the most distressing vasomotor symptoms during perimenopause, was significantly reduced in the SHT group over the 8-week study period (p = 0.002). Significant reductions in fatigue and improvements in vigor were also observed, consistent with the adaptogenic properties attributed to Shatavari; additionally, perceived stress showed a progressive and statistically significant reduction in the SHT group compared to placebo. No adverse events were reported during this study.

A larger three-arm, multicenter, randomized, double-blind, placebo-controlled study (2025) tested Shatavari alone and in combination with ashwagandha. This 8-week study enrolled 135 women aged 45–65 years, randomized into three groups: SHT (n=45), a combination arm (ARE-SHT; n=45), or placebo (PL; n=45), with the primary outcome evaluated by change in the Menopause Rating Scale (MRS) score at weeks 4 and 8. The Shatavari extract used was standardized to a total Shatavarin content of >10% by HPLC.

Evidence assessment: Recent double-blind RCTs using standardized extracts (≥300 mg/d; >10% shatavarins) have reported statistically significant improvements in hot flash frequency, perceived stress, fatigue, and quality-of-life scores in perimenopausal and menopausal women. However, trials remain relatively small and of short duration (8 weeks), and independent replication is needed before conclusions can be firmly drawn.

4.3 Immunomodulation

Asparagus racemosus is of therapeutic interest due to its role as an immunomodulant, galactogogue, adaptogen, antitussive, anticarcinogen, antioxidant, antidiarrheal, and as a general tonic. In vitro produced steroidal saponins of A. racemosus had similar immunomodulatory properties to natural plant root extract; the in vitro produced shatavarins stimulated immune cell proliferation and IgG secretion in a dose-dependent manner.

In a murine model, Shatavarin IV at 40 μg produced a better humoral immune response (comparable to the standard saponin adjuvant Quil-A at 10 μg). This was attributed to the structural characteristics of Shatavarin IV. These findings are preclinical only; robust human immunological trials with shatavarins as isolated compounds are lacking.

Evidence assessment: Current immunomodulatory evidence is primarily from cell culture and animal studies. Human clinical data are limited. Evidence is preliminary and should be characterized as such.

4.4 Gastrointestinal and Antiulcer Activity

Asparagus racemosus is recommended in Ayurvedic texts for prevention and treatment of gastric ulcers and dyspepsia. Recent studies suggest prebiotic-like activity, promoting beneficial Lactobacillus and Bifidobacterium growth. A study showed Shatavari stimulates gastric emptying similarly to the synthetic dopamine antagonist metoclopramide.

No scientific proof justifying aforementioned uses of root extract of A. racemosus for nervous disorders, liver diseases, and infectious diseases is available so far. Antiulcer data remain principally from animal (rodent) model experiments, with limited and methodologically modest human data.

Evidence assessment: Largely preclinical (animal models and cell studies). One published study demonstrated effects on gastric emptying time in healthy volunteers. Robust human clinical trial data are absent for the antiulcer indication.

4.5 Skeletal Muscle Strength and Exercise Adaptation

This is an emerging research area. Shatavari has long been used as an Ayurvedic herb for women's health, but empirical evidence for effectiveness had been lacking; Shatavari contains phytoestrogenic compounds that bind to the estradiol receptor, and postmenopausal estradiol deficiency contributes to sarcopenia and osteoporosis. In a randomized double-blind trial, 20 postmenopausal women (68.5 ± 6 years) ingested either placebo (N=10) or shatavari (N=10; 1000 mg/d, equivalent to 26,500 mg/d fresh weight shatavari) for 6 weeks. Six weeks of shatavari supplementation improved handgrip strength and increased markers of myosin contractile function.

A follow-on proteomics analysis of the same trial's vastus lateralis (VL) biopsies investigated potential mechanisms. No individual protein was significantly different between supplementation conditions, but both PADOG and CAMERA pathway analyses indicated that pathways related to (1) Integrin/MAPK signalling, (2) metabolism/insulin secretion, (3) cell proliferation/senescence/DNA repair/cell death, (4) haemostasis/platelets/fibrin, (5) signal transduction, (6) neutrophil degranulation, and (7) chemical synapse function were significantly upregulated. Analyses indicated that shatavari may support muscle adaptation responses to exercise; these data provide useful signposts for future investigation of shatavari's utility in conserving and enhancing musculoskeletal function in older age.

Evidence assessment: Preliminary positive signal from a very small randomized trial (n=20) and proteomics sub-study. Results are exploratory; replication in larger populations is needed.

4.6 Anticancer Activity

Preclinical anticancer investigations have concentrated on isolated shatavarin IV. The present investigation evaluated the anticancer activity of major shatavarins (shatavarin IV) from the AR-2B fraction of Asparagus racemosus roots; in vitro cytotoxicity study using MCF-7, HT-29, and A-498 cell lines showed potent activity with AR-2B (5.05% shatavarin IV) as well as its isolated compound. Oral administration of AR-2B to tumor-bearing mice at doses of 250 and 500 mg/kg body weight for 10 days showed significant reduction in tumor percent.

Shatavarin IV has also been investigated in the context of gastric adenocarcinoma. The therapeutic efficacy of Shatavarin IV — a major steroidal saponin from the roots of A. racemosus — was assessed in human gastric adenocarcinoma cell lines (AGS) under hyperglycemic conditions, exploring its mechanism of action in controlling cancer progression.

Evidence assessment: All anticancer data are from in vitro cell culture studies and animal models. No human clinical trials have been conducted. These findings are early-stage and should not be interpreted as evidence of clinical anticancer efficacy.

4.7 Neuroprotection and Cognitive Function

Shatavarins I to VI enhanced memory and protected against scopolamine-induced amnesia in rodents. Shatavarin IV, a steroidal saponin in Asparagus racemosus, is a traditionally recognized phytotherapeutic for cognitive ailments; its neuroprotective action was investigated in cultured SH-SY5Y cells. In LPS-induced cells treated with shatavarin IV, pro-inflammatory cytokines IL-6 and TNFα were significantly reduced while anti-inflammatory mediators IL-10 and TGF-β were upregulated, accompanied by reductions in ROS and NO levels.

An enzyme-treated extract of Asparagus racemosus (ETAS) improved sleep quality and reduced fatigue and psychological distress under stress conditions in a published human study. This represents one of the few human-level data points for neurological effects. Evidence assessment: Neuroprotective and cognitive effects are primarily from rodent models and cell culture; one human study with a specific enzymatic extract showed effects on sleep/fatigue. Clinical evidence for direct cognitive or neuroprotective outcomes is insufficient.

4.8 Adaptogenic and Stress-Modifying Properties

Asparagus racemosus is credited with exerting adaptogenic effects through its steroidal saponins. In the perimenopause RCT, significant reductions in fatigue and improvements in vigor were observed, consistent with the adaptogenic properties attributed to Shatavari; perceived stress showed a progressive and statistically significant reduction in the SHT group compared to placebo. Significant reductions in fatigue and improvements in vigor were observed in the POMS assessment, consistent with adaptogenic properties attributed to Shatavari.

Evidence assessment: Adaptogenic effects (stress reduction, fatigue reduction) have been documented in RCTs as secondary outcomes. These data are promising but require dedicated, adequately powered primary-outcome trials.

5. Body Systems and Health Areas

Female Reproductive System: Steroidal saponins (phytoestrogen-like) form the majority of bioactive phytoconstituents of Asparagus species and are well-known for promoting male and female reproductive health both clinically and preclinically.
Endocrine / Hormonal System: Shatavari is believed to exert its effects through phytoestrogenic activity of its steroidal saponins (shatavarins), which have affinity for estrogen receptors and may modulate gonadotropin levels, in addition to antioxidant and anti-inflammatory actions.
Immune System: As an immunomodulator, Shatavari enhances the function of macrophages and lymphocytes, potentially improving immune-endocrine interactions within the female reproductive tract.
Gastrointestinal System: Shatavari is commonly prescribed in Ayurveda for hyperacidity, gastritis, peptic ulcers, and intestinal inflammation.
Skeletal Muscle / Musculoskeletal System: Analyses indicate that shatavari may support muscle adaptation responses to exercise.
Nervous System: Shatavarin IV, a steroidal saponin in A. racemosus, is a traditionally recognized phytotherapeutic for the treatment of cognitive ailments.
Mammary Gland and Lactation: The administration of alcoholic extract of its rhizome in adult pregnant female albino rats suggests an estrogenic effect of Shatavari on the female's mammary gland and genital organs.

6. Dosage Forms and Reported Dosages

Dosages reported across published clinical studies vary by formulation, indication, and population. The following are dosages as stated in the cited studies:

Perimenopause / Menopausal symptoms: An 8-week oral administration of Shatavari root extract at 300 mg once daily was assessed in women with perimenopausal symptoms. The three-arm menopausal symptom trial used a 300 mg Shatavari root extract capsule or a combination capsule containing 300 mg Shatavari and 250 mg Ashwagandha, taken once daily after breakfast with water for 8 weeks.
Postpartum lactation: In one lactation RCT (n=120), participants received either Shatavari root extract (300 mg) or placebo capsules twice daily for 72 hours postpartum.
Skeletal muscle / postmenopausal women: In a randomized double-blind trial, 20 postmenopausal women ingested either placebo (N=10) or shatavari (N=10; 1000 mg/d, equivalent to 26,500 mg/d fresh weight shatavari) for 6 weeks.
Adjuvant activity (preclinical): In a murine model, Shatavarin IV at 40 μg produced a notable humoral immune response.
Anticancer (preclinical): Oral administration of AR-2B to tumor-bearing mice at doses of 250 and 500 mg/kg body weight for 10 days was used in the in vivo study.

A key approach is the use of a standardized Shatavari root extract containing >10% shatavarins as the defining quality parameter for clinically employed extracts.

7. Safety Considerations and Drug Interactions

7.1 General Safety Profile

While Asparagus racemosus (Shatavari) is generally regarded as a safe and well-tolerated medicinal plant with centuries of traditional use, it is essential to evaluate its safety profile critically in the context of modern pharmacovigilance.

Shatavari is regarded as safe for use during pregnancy and lactation by Ayurvedic practitioners, but the plant is not listed as having "generally recognized as safe" (GRAS) status by the US Food and Drug Administration (FDA). Clinical studies and case reports are lacking to provide comprehensive information regarding adverse effects.

In recent clinical trials, the safety record has been favorable. No adverse events were reported during the 8-week perimenopause RCT. No maternal or neonatal adverse events were observed in the Shavari Bar lactation trial.

7.2 Gastrointestinal Adverse Effects

Mild gastrointestinal complaints are among the most reported adverse effects associated with Shatavari usage, particularly at higher doses or in individuals with sensitive digestive systems; these symptoms are usually transient and dose-dependent, often resolving upon dose reduction or discontinuation.

7.3 Allergic Reactions

Asparagus racemosus might cause an allergic reaction in people who are sensitive to other members of the order Asparagales including onions, leeks, garlic, and chives. Individuals with asparagus-family sensitivities should exercise caution, as cross-reactivity within the broader Asparagales order has been described.

7.4 Cardiovascular Considerations

At higher than recommended dosages, adverse cardiovascular effects may occur, based on limited animal studies. This finding has not been confirmed in human clinical trials to date, and the clinical significance remains unknown.

7.5 Hemolytic Activity of Shatavarin IV

Shatavarin IV exhibited hemolytic activity at very low concentrations due to its core steroidal nucleus; this promotes the binding of saponin with the phospholipid membrane of red blood cells and initiates hemolysis by a membrane perturbation mechanism. This property is shared with many plant saponins and is relevant for parenteral use, though oral administration is expected to limit systemic exposure.

7.6 Estrogenic Activity Considerations

Studies in rodents suggest estrogenic effects of A. racemosus. Phytoestrogens in Shatavari are believed to modulate estrogenic activity by binding to estrogen receptors. The clinical implications of this estrogenic activity for individuals with hormone-sensitive conditions have not been systematically evaluated in well-designed human trials.

7.7 Conservation Status

This plant is facing the threat of being endangered due to several developmental, seasonal constraints, and malpractices involved in its collection and storage. Currently, the plant is considered endangered in its natural habitat because of destructive harvesting, habitat destruction, and deforestation. This has spurred research into tissue culture methods as an alternative production strategy.

References

Health Conditions

Health conditions that Shataverins may help support.

No conditions available.

Body Systems

Body systems that Shataverins may help support.

No body systems available.